From: medicalxpress.com A new finding provides fresh hope for the millions of women worldwide with oestrogen receptor positive breast cancer. Australian scientists have shown that a specific change, which occurs when tumours become resistant to anti-oestrogen therapy, might make the cancers susceptible to treatment with chemotherapy drugs. Seventy percent of breast cancer patients have oestrogen receptor positive cancer, and most …
CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer
(Menafn – M2 PRESSWIRE via COMTEX) New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients’ time Herceptin is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (six:RO)(six:ROG)(otcqx:RHHBY) is pleased to announce that the …
New urine-based test to detect breast cancer
From Zee News Washington: Scientists have developed a new urine-based screening method to diagnose breast cancer and determine its severity even before it can be detected with a mammogram. A Missouri University of Science and Technology researcher used a device called a P-scan, to detect the concentration of certain metabolites called pteredines in urine samples. These biomarkers are present in …
TissuGlu® Surgical Adhesive Has the Potential to Eliminate Drains, Improving Patient Recovery
PITTSBURGH, Pa., May 14, 2013 – Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced it has completed a series of mastectomy procedures in Munich and Berlin, Germany using TissuGlu® Surgical Adhesive without drain placement. With this innovative adhesive technology, surgeons were able to eliminate the need for closed-suction drains on breast cancer patients …